Simulations Plus, Inc (NASDAQ:SLP) Acquisition Lifts Near-Term Valuation Potential

Acquisition activity and solid operating cash metrics set a constructive near-term posture for the company. Fundamentals show strong liquidity and positive free cash generation while technicals flag a mixed momentum picture.

Recent News

On June 16, 2026 the company entered into a definitive agreement to be acquired by affiliates of Altaris, LLC in an all-cash transaction valuing the deal at roughly $375 million and providing $18.50 per share to stockholders, cited as a premium to recent trading.

Technical Analysis

ADX at 39.89 signals a strong trend environment; such trend strength increases the odds that current directional forces persist over the near term and therefore amplifies any price reaction tied to corporate news or takeover dynamics.

Directional indicators show DI+ at 26.65 with a peak-and-reversal pattern, which reads as bearish momentum on directional breadth; DI- at 11.46 trends decreasing, which provides a partial offset but does not negate the DI+ peak-and-reversal bearish interpretation.

MACD sits at 0.14 below its signal line at 0.18 with a peak-and-reversal MACD trend, indicating bearish momentum and that momentum has recently weakened relative to its prior run.

MRO at 17.36 with a peak-and-reversal profile places price above the model target and therefore signals potential for mean reversion toward that target; the positive MRO implies limited immediate upside pressure absent fresh buying catalysts.

RSI at 63.17 with a dip-and-reversal pattern reads bullish on short-term price recovery pressure; this suggests intraday/short-horizon strength may persist even while momentum indicators (MACD, DI+) show strain.

Price sits above the 12- and 26-day EMAs (price12dayEMA 18.34 increasing; price26dayEMA 18.23), and above short- and long-term averages (20-day 18.34, 50-day 17.99, 200-day 16.27). Tight Bollinger band widths (upper ~18.37, lower ~18.31) indicate compressed volatility; low recent volumes relative to moving averages reduce follow-through risk for any breakout move.

 


Fundamental Analysis

Revenue totaled $21,886,000 for the period ending May 31, 2026. Year-over-year revenue growth registers +7.35% while the most recent quarter shows a pronounced QoQ decline; the YoY improvement contrasts with quarter-to-quarter timing effects and seasonal variability.

Operating performance shows EBIT $4,499,000 and EBITDA $5,867,000, with an operating (EBIT) margin of 20.56%. That EBIT margin sits below the industry peer mean of 22.914% and well under the industry peer median of 30.932%, while still representing a meaningful YoY improvement of +39.77% and a QoQ contraction of -11.30%.

Profitability returns remain low in absolute terms: return on assets 2.39% and return on equity 2.57%, both marginally below the industry peer means for those measures. Net income reached $3,575,000 and EPS came in at $0.30 versus an estimate of $0.23, producing an EPS surprise ratio of +30.44%.

Liquidity and balance-sheet strength stand out: cash $35,324,000, cash and short-term investments $49,990,000, current ratio 5.54 and cash ratio 3.68. Total debt equals $487,000, producing negligible leverage (debt to assets ~0.32%). The company converts earnings to cash efficiently (cash flow to earnings ~205%) and free cash flow equals $7,948,000 with a free cash flow yield of 2.42%.

Valuation metrics show a trailing P/E of 54.17 and a forward P/E near 65.61; enterprise multiple registers 47.56 while EV/Revenue (EVR) sits at 12.75. WMDST values the stock as under-valued, a conclusion driven by exceptionally strong liquidity, minimal leverage, and positive free cash generation despite high multiple metrics that reflect growth expectations and transaction premium dynamics. Recent investor materials and the company’s third-quarter fiscal 2026 disclosure provide the underlying results and context for these fundamental points.

MOST-RECENT QUARTERLY REPORT
REPORT PERIOD ENDING: 2026-05-31
REPORT DATE: 2026-07-09
NEXT REPORT DATE: 2026-10-08
CASH FLOW  Begin Period Cash Flow 25.7 M
 Operating Cash Flow 8.7 M
 Capital Expenditures -761.00 K
 Change In Working Capital
 Dividends Paid
 Cash Flow Delta 9.6 M
 End Period Cash Flow 35.3 M
 
INCOME STATEMENT REVENUE
 Total Revenue 21.9 M
 Forward Revenue 6.8 M
COSTS
 Cost Of Revenue 6.8 M
 Depreciation 1.4 M
 Depreciation and Amortization 1.4 M
 Research and Development 3.4 M
 Total Operating Expenses 17.4 M
PROFITABILITY
 Gross Profit 15.1 M
 EBITDA 5.9 M
 EBIT 4.5 M
 Operating Income 4.5 M
 Interest Income 344.0 K
 Interest Expense
 Net Interest Income 344.0 K
 Income Before Tax 4.8 M
 Tax Provision 1.2 M
 Tax Rate 26.0 %
 Net Income 3.6 M
 Net Income From Continuing Operations 3.6 M
EARNINGS
 EPS Estimate 0.23
 EPS Actual 0.30
 EPS Difference 0.07
 EPS Surprise 30.435 %
 Forward EPS 0.22
 
BALANCE SHEET ASSETS
 Total Assets 153.0 M
 Intangible Assets 71.4 M
 Net Tangible Assets 67.6 M
 Total Current Assets 75.1 M
 Cash and Short-Term Investments 50.0 M
 Cash 35.3 M
 Net Receivables 17.2 M
 Inventory
 Long-Term Investments 1.4 M
LIABILITIES
 Accounts Payable 2.2 M
 Short-Term Debt
 Total Current Liabilities 13.6 M
 Net Debt
 Total Debt 487.0 K
 Total Liabilities 13.9 M
EQUITY
 Total Equity 139.0 M
 Retained Earnings -25.58 M
VALUATION & PER-SHARE METRICS EQUITY & PER-SHARE METRICS
 Book Value Per-Share 6.88
 Shares Outstanding 20.216 M
 Revenue Per-Share 1.08
VALUATION
 Market Capitalization 328.5 M
 Enterprise Value 279.0 M
 Enterprise Multiple 47.561
Enterprise Multiple QoQ 44.688 %
Enterprise Multiple YoY -20.434 %
Enterprise Multiple IPRWA high: 137.95
median: 73.952
mean: 67.88
SLP: 47.561
low: -20.4
 EV/R 12.75
CAPITAL STRUCTURE
 Asset To Equity 1.1
 Asset To Liability 10.973
 Debt To Capital 0.003
 Debt To Assets 0.003
Debt To Assets QoQ -8.357 %
Debt To Assets YoY -40.561 %
Debt To Assets IPRWA high: 0.576
mean: 0.042
median: 0.011
low: 0.009
SLP: 0.003
 Debt To Equity 0.004
Debt To Equity QoQ -7.895 %
Debt To Equity YoY -39.759 %
Debt To Equity IPRWA high: 3.104
mean: 0.107
median: 0.014
low: 0.011
SLP: 0.004
PRICE-BASED VALUATION
 Price To Book (P/B) 2.363
Price To Book QoQ 14.016 %
Price To Book YoY -15.297 %
Price To Book IPRWA high: 5.885
median: 3.869
mean: 3.531
SLP: 2.363
low: 0.094
 Price To Earnings (P/E) 54.171
Price To Earnings QoQ 38.178 %
Price To Earnings YoY 0.456 %
Price To Earnings IPRWA high: 220.299
median: 77.436
mean: 72.271
SLP: 54.171
low: -35.545
 PE/G Ratio -3.792
 Price To Sales (P/S) 15.012
Price To Sales QoQ 31.524 %
Price To Sales YoY -11.478 %
Price To Sales IPRWA high: 50.378
median: 32.011
mean: 26.968
SLP: 15.012
low: 0.761
FORWARD MULTIPLES
Forward P/E 65.611
Forward PE/G -4.593
Forward P/S 48.129
EFFICIENCY OPERATIONAL
 Operating Leverage 2.029
ASSET & SALES
 Asset Turnover Ratio 0.146
Asset Turnover Ratio QoQ -14.455 %
Asset Turnover Ratio YoY 20.513 %
Asset Turnover Ratio IPRWA high: 0.353
SLP: 0.146
mean: 0.111
median: 0.098
low: 0.028
 Receivables Turnover 1.237
Receivables Turnover Ratio QoQ -22.759 %
Receivables Turnover Ratio YoY -4.975 %
Receivables Turnover Ratio IPRWA high: 2.963
SLP: 1.237
mean: 1.099
median: 0.966
low: 0.949
 Inventory Turnover
Inventory Turnover Ratio QoQ
Inventory Turnover Ratio YoY
Inventory Turnover Ratio IPRWA
 Days Sales Outstanding (DSO) 73.739
CASH CYCLE
 Cash Conversion Cycle Days (CCC) 56.733
Cash Conversion Cycle Days QoQ 21.064 %
Cash Conversion Cycle Days YoY
Cash Conversion Cycle Days IPRWA high: 94.513
median: 69.215
mean: 57.951
SLP: 56.733
low: -15.96
CAPITAL DEPLOYMENT
 Cash Conversion Ratio 0.356
 CapEx To Revenue -0.035
 CapEx To Depreciation -0.556
 
CAPITAL, LIQUIDITY & COVERAGE CAPITAL STRUCTURE
 Total Capital 139.0 M
 Net Invested Capital 139.0 M
 Invested Capital 139.0 M
 Net Tangible Assets 67.6 M
 Net Working Capital 61.6 M
LIQUIDITY
 Cash Ratio 3.685
 Current Ratio 5.538
Current Ratio QoQ 1.173 %
Current Ratio YoY 8.359 %
Current Ratio IPRWA high: 9.945
SLP: 5.538
median: 4.738
mean: 4.343
low: 1.021
 Quick Ratio
Quick Ratio QoQ
Quick Ratio YoY
Quick Ratio IPRWA
COVERAGE & LEVERAGE
 Debt To EBITDA 0.083
 Cost Of Debt 109.867 %
 Interest Coverage Ratio 6.123
Interest Coverage Ratio QoQ -20.089 %
Interest Coverage Ratio YoY 50.217 %
Interest Coverage Ratio IPRWA high: 33.284
median: 9.029
mean: 8.316
SLP: 6.123
low: -15.488
 Operating Cash Flow Ratio 0.541
TIMING / LIQUIDITY
 Days Payables Outstanding (DPO) 17.006
DIVIDENDS
 Dividend Coverage Ratio
 Dividend Payout Ratio
 Dividend Rate
 Dividend Yield
PERFORMANCE GROWTH
 Asset Growth Rate 4.432 %
 Revenue Growth -9.901 %
Revenue Growth QoQ -131.071 %
Revenue Growth YoY 7.351 %
Revenue Growth IPRWA high: 7.736 %
median: 5.622 %
mean: 4.758 %
SLP: -9.901 %
low: -12.762 %
 Earnings Growth -14.286 %
Earnings Growth QoQ -108.442 %
Earnings Growth YoY -131.633 %
Earnings Growth IPRWA high: 122.222 %
mean: 8.999 %
median: 8.738 %
SLP: -14.286 %
low: -200.0 %
MARGINS
 Gross Margin 69.117 %
Gross Margin QoQ 4.003 %
Gross Margin YoY 7.999 %
Gross Margin IPRWA high: 89.522 %
median: 74.979 %
mean: 72.554 %
SLP: 69.117 %
low: 12.388 %
 EBIT Margin 20.557 %
EBIT Margin QoQ -11.304 %
EBIT Margin YoY 39.767 %
EBIT Margin IPRWA high: 30.932 %
median: 30.932 %
mean: 22.914 %
SLP: 20.557 %
low: -79.321 %
 Return On Sales (ROS) 20.557 %
Return On Sales QoQ -11.304 %
Return On Sales YoY 39.767 %
Return On Sales IPRWA high: 30.932 %
median: 30.932 %
mean: 23.055 %
SLP: 20.557 %
low: -81.621 %
CASH FLOW
 Free Cash Flow (FCF) 7.9 M
 Free Cash Flow Yield 2.419 %
Free Cash Flow Yield QoQ 20.169 %
Free Cash Flow Yield YoY 18.404 %
Free Cash Flow Yield IPRWA high: 6.843 %
median: 3.988 %
mean: 3.135 %
SLP: 2.419 %
low: -14.954 %
 Free Cash Growth 42.437 %
Free Cash Growth QoQ -37.006 %
Free Cash Growth YoY -13.183 %
Free Cash Growth IPRWA high: 219.25 %
SLP: 42.437 %
mean: -13.127 %
median: -52.29 %
low: -308.543 %
 Free Cash To Net Income 2.223
 Cash Flow Margin 33.547 %
 Cash Flow To Earnings 2.054
VALUE & RETURNS
 Economic Value Added 0.04
 Return On Assets (ROA) 2.388 %
Return On Assets QoQ -25.141 %
Return On Assets YoY -105.956 %
Return On Assets IPRWA high: 2.882 %
median: 2.882 %
SLP: 2.388 %
mean: 2.239 %
low: -10.518 %
 Return On Capital Employed (ROCE) 3.227 %
 Return On Equity (ROE) 0.026
Return On Equity QoQ -24.159 %
Return On Equity YoY -104.727 %
Return On Equity IPRWA high: 0.064
median: 0.036
mean: 0.027
SLP: 0.026
low: -0.174
 DuPont ROE 2.621 %
 Return On Invested Capital (ROIC) 2.407 %
Return On Invested Capital QoQ -25.779 %
Return On Invested Capital YoY 9.409 %
Return On Invested Capital IPRWA high: 3.643 %
median: 2.808 %
SLP: 2.407 %
mean: 2.053 %
low: -10.271 %

Six-Week Outlook

Takeover terms and high cash reserves concentrate near-term attention around the announced $18.50 per-share consideration; technicals form a mixed signal set. Strong ADX amplifies the current directional bias while a MACD peak-and-reversal and positive MRO suggest limited upside beyond deal-related valuation without renewed momentum. RSI’s dip-and-reversal supports short bursts of strength, and short-term EMAs sit marginally below price, offering technical support. Expect price action to trade with compressed volatility and to remain sensitive to deal progress updates and any regulatory or financing disclosures tied to the transaction announcement.

About Simulations Plus, Inc.

Simulations Plus, Inc. (NASDAQ:SLP) develops advanced software solutions for drug discovery and development, leveraging artificial intelligence and machine learning technologies. The company operates through its Software and Services segments, offering a range of products designed to simulate and predict molecular properties and interactions. Key offerings include GastroPlus, which models the absorption and interaction of compounds in humans and animals, as well as DDDPlus and MembranePlus simulation tools. Simulations Plus also provides mechanistic and mathematical model-based products such as DILIsym, NAFLDsym, ILDsym, IPFsym, RENAsym, MITOsym, and OBESITYsym. These products assist in understanding complex biological systems and drug interactions. The company offers the ADMET Predictor, a chemistry-based program that predicts molecular properties from structures, and the MedChem Designer for molecular design and analysis. Additionally, Simulations Plus delivers consulting services in clinical pharmacology, including population pharmacokinetic and pharmacodynamic modeling, exposure-response analyses, and clinical trial simulations. Their consulting services support regulatory submissions and early drug discovery efforts. The company’s clientele spans pharmaceutical, biotechnology, agrochemical, cosmetics, and food industries, as well as academic and regulatory institutions. Established in 1996, Simulations Plus is headquartered in Lancaster, California.



© 2026 WMDST — The World’s Most Dangerous Swing Trader. All rights reserved.